Growth Hormone
Ipamorelin
Selective ghrelin/GHS-R agonist that raises GH without significantly affecting cortisol or prolactin.
- Half-life
- ~2 hours
- Route
- Subcutaneous
Overview
Ipamorelin is a pentapeptide growth-hormone secretagogue developed by Novo Nordisk as a cleaner alternative to earlier GHRPs.
Mechanism of action
Binds the ghrelin (GHS-R1a) receptor on somatotrophs, triggering GH release. Unlike GHRP-6 and GHRP-2, it does not measurably raise cortisol, ACTH or prolactin at typical doses.
Evidence base
Human pharmacology studies confirm dose-dependent GH pulses without HPA-axis activation. Never advanced past phase 2 for its original postoperative ileus indication.
Typical dosing
Research protocols commonly 200–300 mcg subcutaneously, 1–3 times daily, most often at bedtime and pre-workout. Open the dose calculator →
Safety & contraindications
Mild flushing or head rush shortly after injection is common. Long-term human safety data limited.
Common stacks
Standard pairing with CJC-1295 or sermorelin (GHRH + GHRP synergy).
Related peptides
Educational reference only. Nothing on this page is medical advice, a prescription, or an offer to sell. Discuss any peptide therapy with a qualified clinician who can evaluate your history and monitoring needs.